{"id":"anavex2-73-oral-liquid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL2108930","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Sigma-1 receptor agonists are a class of compounds that activate the sigma-1 receptor, a protein involved in various cellular processes. ANAVEX2-73 is being investigated for its potential therapeutic effects in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.","oneSentence":"ANAVEX2-73 is an oral liquid formulation of a sigma-1 receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:18.340Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"},{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT04304482","phase":"PHASE2, PHASE3","title":"ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2020-07-01","conditions":"Rett Syndrome","enrollment":92},{"nctId":"NCT03941444","phase":"PHASE3","title":"ANAVEX2-73 Study in Patients With Rett Syndrome","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2019-05-06","conditions":"Rett Syndrome","enrollment":33},{"nctId":"NCT03758924","phase":"PHASE2","title":"Study of ANAVEX2-73 in Patients With Rett Syndrome","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2019-02-28","conditions":"Rett Syndrome","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Blarcamesine"],"phase":"phase_2","status":"active","brandName":"ANAVEX2-73 oral liquid","genericName":"ANAVEX2-73 oral liquid","companyName":"Anavex Life Sciences Corp.","companyId":"anavex-life-sciences-corp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ANAVEX2-73 is an oral liquid formulation of a sigma-1 receptor agonist. Used for Alzheimer's disease, Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}